#+TITLE: Sphingolipid Degradation: GM1/2 Gangliosidosis
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

* Introduction
- *\beta-hexosaminidase A* deficiency 
  - impaired lysosomal catabolism of GM2 ganglioside
- progressive cerebral degeneration
- functional lysosomal \beta-hexosaminidase enzymes are dimeric
  - three isozymes are produced through the combination of \alpha
    and \beta subunits (Table [[tab:hexiso]])

#+CAPTION[]:Hexoaminidase Isozymes
#+NAME: tab:hexiso
| Isozyme | Dimer composition | Function                                   |
|---------+-------------------+--------------------------------------------|
| A       | \alpha/\beta      | hydrolyzes GM2 ganglioside                 |
| B       | \beta/\beta       | non-GM2 gangliosides w terminal hexosamine |
| S       | \alpha/\alpha     | no known physiological function            |

- \beta-galactosidase, hexoaminidase A and B require the M6P-receptor
  - secreted in ML II (I cell disease)
- GM2 activator protein - sortilin

- three genetic and biochemical subtypes
  - Tay-Sachs disease ::  \alpha-subunit \to Hex A deficiency 
  - Sandhoff disease :: \beta-subunit \to Hex A&B deficiencies
  - GM2 activator deficiency :: activator \to AB variant 
- GM2 storage in neurons in Tay-Sachs and Sandhoff
  - Sandhoff \uparrow asialo-GM2 in brain, globoside and oligosacarides in viseral organs


#+CAPTION[]:GM2 ganglioside storage diseases
#+NAME: tab:gm2
| Disorder     | Onset       | Death (y) | Enzyme    | Gene |
|--------------+-------------+-----------+-----------+------|
| Tay-Sachs    | 3-6 months  |       2-4 | Hex A     | HEXA |
| Juvenile GM2 | 2-6 years   |      5-15 | Hex A     | HEXA |
| Adult GM2    | 2 yrs-adult |  variable | Hex A     | HEXA |
|--------------+-------------+-----------+-----------+------|
| Sandhoff     | 3-6 months  |       2-4 | Hex A&B   | HEXB |
| AB variant   | 3-6 months  |           | Activator | GM2A |

#+CAPTION[]:Hexosaminidase A: Tay-Sachs
#+NAME: fig:hexa
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/hexosaminidasea.png]]


#+CAPTION[]:Hexosaminidase A & B:Sandhoff disease [fn:gl]
#+NAME: fig:hexb
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/hexosaminidaseab.png]]

[fn:gl] GL-3 & 4 AKA Gb3 & 4

* Clinical Findings
- see table [[tab:gm2ss]]
#+CAPTION[]:GM2 Signs and Symptoms
#+NAME: tab:gm2ss
| Finding           | Infantile         | Juvenile           | Adult            |
|-------------------+-------------------+--------------------+------------------|
| onset of symptoms | <1 year           | 2-10 years         | 10+ years        |
| eye findings      | CRS, blindness    | \pm CRS            |                  |
| movement          | weakness          | ataxia, dysarthria | dystonia, ataxia |
| neurological      | startle response  | seizures           | psychosis        |
|                   | seizures          |                    |                  |

* Genetics
- AR HEXA, HEXB and GM2A
- > 130 mutations in HEXA
  - ~ 3 alleles comprise ~95% of Askenazi Jewish disease alleles
  - good correlation with phenotype 
- > 40 mutations in HEXB
- 6 in GM2A
* Laboratory Investigations
- urine oligosacarides
- /in vitro/ hexoaminidase activity: leukocytes, fibroblasts
  - 4-MU-6-sulfo-\beta-glucosaminide
  - specific for the \alpha subunit
- falsely normal results in Tay-Sachs female carriers
- the direct assay of hexosaminidase A using the sulfated synthetic
  substrate (4-MU-6-sulfo-/beta-glucosaminide) specific for the \alpha-subunit
  is the method of choice
- total hexosaminidases (A+B) using a synthetic fluorogenic substrate
  allows the diagnosis of Sandhoff disease
- differential assay of HexA using heat or acid
  inactivation does not identify patients with the B1 variant

- high residual activity is found in Sandhoff disease
  - excess of hexosaminidase S (\alpha\alpha-dimer)
- GM2 activator deficiency
  - normal /in vitro/ hexosaminidase A activity
  - definitive diagnosis requires GM2A sequencing
- electron microscopic examination of a skin or conjunctiva biopsy
  - concentric lamellated bodies in nerve endings
- \uparrow CSF GM2

* Treatment
- treat seizures
- no curative treatment to date





